Missed Opportunities: Despite Improvement in Use of Cardioprotective Medications Among Patients With Lower-Extremity Peripheral Artery Disease, Underuse Remains

Patients with peripheral artery disease (PAD) are at high risk of cardiovascular events and benefit from aggressive secondary prevention; however, changes in the use of cardioprotective medications after incident diagnosis of PAD have not been well described. We used Danish nationwide administrative...

Full description

Saved in:
Bibliographic Details
Published in:Circulation (New York, N.Y.) N.Y.), 2012-09, Vol.126 (11), p.1345-1354
Main Authors: SUBHERWAL, Sumeet, PATEL, Manesh R, KOBER, Lars, PETERSON, Eric D, JONES, William S, GISLASON, Gunnar H, BERGER, Jeffrey, TORP-PEDERSEN, Christian, FOSBOL, Emil L
Format: Article
Language:English
Subjects:
Aged
Aged, 80 and over
Angiotensin-Converting Enzyme Inhibitors - therapeutic use
Biological and medical sciences
Blood and lymphatic vessels
Cardiology. Vascular system
Cardiotonic Agents - therapeutic use
Cohort Studies
Coronary Disease - epidemiology
Coronary Disease - prevention & control
Denmark
Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous
Female
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use
Incidence
Lower Extremity
Male
Medical sciences
Middle Aged
Peripheral Arterial Disease - complications
Peripheral Arterial Disease - diagnosis
Peripheral Arterial Disease - drug therapy
Platelet Aggregation Inhibitors - therapeutic use
Registries
Retrospective Studies
Risk Factors
Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis
Secondary Prevention - methods
Secondary Prevention - trends
Treatment Outcome
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Patients with peripheral artery disease (PAD) are at high risk of cardiovascular events and benefit from aggressive secondary prevention; however, changes in the use of cardioprotective medications after incident diagnosis of PAD have not been well described. We used Danish nationwide administrative registries (2000-2007) to identify 2 groups with incident PAD: PAD alone (n=34 160) and PAD with history of coronary artery disease (CAD) (n=9570). With the use of a comparator with incident CAD alone (n=154 183), we assessed temporal trends and comparative use of cardioprotective medications. Relative differences in medication use were examined by using multivariable logistic regression. Use of medications improved temporally among both groups: for PAD alone, any antiplatelet use increased from 29% to 59% from 2000 to 2007 (P
ISSN:0009-7322
1524-4539
DOI:10.1161/CIRCULATIONAHA.112.108787